18453-32-2

Microtubule targeting agents (MTAs) are among the most successful chemotherapeutic drugs, but their efficacy is often limited by the development of multidrug resistance (MDR). Therefore, the development of novel MTAs with the ability to overcome MDR is urgently needed. In this contribution, through modification of the unsymmetric biaryl compounds, we discovered a novel compound dxy-1-175 with potent anti-proliferative activity against cancer cells. Mechanistic study revealed that dxy-1-175 inhibited tubulin polymerization by interacting with the colchicine-binding site of tubulin, which caused cell cycle arrest at G2/M phase. Based on the predicted binding model of dxy-1-175 with tubulin, a series of new 4-benzoylbiphenyl analogues were designed and synthesized. Among them, the hydrochloride compound 12e with improved solubility and good stability in human liver microsome, exhibited the most potent anti-proliferative activity with IC50 value in the low nanomolar range, and markedly inhibited the growth of breast cancer 4T1 xenograft in vivo. Notably, 12e effectively overcame P-gp-mediated MDR and our preliminary data suggested that 12e may not be a substrate of P-glycoprotein (P-gp). Taken together, our study reveals a novel MTA 12e targeting the colchicine-binding site with potent anticancer activity and the ability to circumvent MDR.

The invention relates to a half-sandwich ruthenium complex containing a phenyl benzoxazole structure as well as a preparation method and application of the half-sandwich ruthenium complex. The ruthenium complex has the following structure as shown in the specification. The preparation method comprises the steps of dissolving phenyl benzoxazole, [CymRuCl2] 2 and sodium acetate in methanol at room temperature, heating the system, and continuing to react; and after the reaction is finished, standing, filtering, carrying out reduced pressure pumping on the solvent, carrying out column chromatography separation on the obtained crude product to obtain the red half-sandwich ruthenium complex containing the phenyl benzoxazole structure, and applying the red half-sandwich ruthenium complex to catalysis of oxidation of alkyl pyridine compounds to prepare nitrogen heterocyclic ketone compounds. Compared with the prior art, the preparation method provided by the invention is simple and green, the catalytic oxidation reaction can be carried out under mild conditions, and the catalyst has high stability and is not sensitive to air and water.

Three sets of conjugated polymers with backbone-donor/pendant-acceptor architectures, named PCzA3PyB, PCzAB2Py, and PCzAB3Py, are designed and synthesized. The three isomeric benzoylpyridine-based pendant acceptor groups are 6-benzoylpyridin-3-yl (3PyB), 4-((pyridin-2-yl)carbonyl)phenyl (B2Py) and 4-((pyridin-3-yl)carbonyl)phenyl (B3Py), whereas the identical backbone consists of 3,6-carbazolyl and 2,7-acridinyl rings. One acridine ring and each acceptor group constitute a definite thermally activated delayed fluorescence (TADF) unit, incorporated into the main chain of the polymers through the 2,7-position of the acridine ring with the varied content. All of the polymers display legible TADF features with a short microsecond-scale delayed lifetime (0.56–1.62 μs) and a small singlet/triplet energy gap (0.10–0.19 eV). Progressively redshifted emissions are observed in the order PCzAB3Py, PCzA3PyB, and PCzAB2Py owing to the different substitution patterns of the pyridyl group. Photoluminescence quantum yields can be improved by regulating the molar content of the TADF unit in the range 0.5–50 %. The non-doped organic light-emitting devices (OLEDs) fabricated by solution-processing technology emit yellow-green to orange light. The polymers with 5 mol % of the TADF unit exhibit excellent comprehensive electroluminescence performance, in which PCzAB2Py5 achieves a maximum external quantum efficiency (EQE) of 11.9 %, low turn-on voltage of 3.0 V, yellow emission with a wavelength of 573 nm and slow roll-off with EQE of 11.6 % at a luminance of 1000 cd m?2 and driving voltage of 5.5 V.

A highly enantioselective transfer hydrogenation of non-ortho-substituted aryl N-heteroaryl ketones, using readily available chiral diamine-derived iridium complex (S,S)-1f as a catalyst and sodium formate as a hydrogen source in a mixture of H2O/i-PrOH (v/v = 1:1) under ambient conditions, is described. The chiral aryl N-heteroaryl methanols were obtained with up to 98.2% ee by introducing an N-oxide as a removable ortho-substituent. In contrast, no more than 15.1% ee was observed in the absence of an N-oxide moiety. Furthermore, the practical utility of this protocol was also demonstrated by gram-scale asymmetric synthesis of bepotastine besilate in 51% total yield and 99.9% ee.

Highly enantioselective pyridine-directed rhodium-catalyzed asymmetric hydrogenation of challenging 1 1-diarylalkenes is achieved by using [Rh(NBD)DuanPhos]BF4 as a precatalyst. Various types of 2-pyridine substituted 1 1-diarylalkenes could be hydrogenated with good to excellent enantioselectivities which provide an efficient route to the synthesis of pharmaceutically and biologically active compounds containing a 2-pyridyl ethane unit.

A practical and highly effective one-pot synthesis of versatile heteroaryl ketones directly from carboxylic acids and heteroaryl halides under mild conditions is reported. This method does not require derivatization of carboxylic acids (preparation of acid chlorides, Weinreb amides, etc.) or the use of any additives/catalysts. A wide substrate scope of carboxylic acids with high functional group tolerance has also been demonstrated. The results reveal that the presence of an α-nitrogen on the halide substrate greatly improves the desired ketone formation.

A facile synthetic approach to the direct preparation of 2-pyridyl and 3-pyridylzinc bromides has been demonstrated using Rieke zinc with 2-bromopyridine and 3-bromopyridine, respectively. A variety of different electrophiles have been coupled with the resulting organozinc reagents to give the corresponding cross-coupling products in moderate to good yields.

Direct preparation of 2-pyridylzinc bromide has been developed. Interestingly, the subsequent coupling reactions with acid chlorides have been carried out without any transition metal catalyst. 2-Pyridylaryl compounds, symmetrical and unsymmetrical 2,2′-b

Compounds of formula I STR1 wherein X, A, B, R1 and R2 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable ester thereof, processes for preparing the compounds and pharmaceutical compositions comprising them. The compounds are useful as potassium channel openers and as therapeutic agents in the treatment of urinary incontinence.